MallInckrodt Plc (MNK)-医療機器分野:企業M&A・提携分析

◆英語タイトル:MallInckrodt Plc (MNK) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011071
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月21日
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Mallinckrodt Plc (Mallinckrodt) is a healthcare products provider that offers generics and active pharmaceutical ingredients. The company offers generic products which include addiction treatment products, compounding powders, unit dose products and resource tool kits. Its active pharmaceutical ingredients comprise acetaminophen and paracetamol; controlled substances and stearates. Mallinckrodt offers nuclear imaging; contrast media and other medical imaging devices. The company also offers contrast media and devices which include advanced integrated softwares, imaging systems, prefilled syringes and others. It markets its products in the UK and abroad. Mallinckrodt is headquartered in Surrey, the UK.

MallInckrodt Plc (MNK) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MallInckrodt Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
MallInckrodt Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
MallInckrodt Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
MallInckrodt Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
MallInckrodt Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
MallInckrodt Plc, Medical Equipment, Deal Details 11
Private Equity 11
Gores Completes Acquisition Of Therakos From Ortho-Clinical Diagnostics 11
Partnerships 12
Mallinckrodt Enters into Licensing Agreement with NeuroproteXeon 12
Bellerophon Therapeutics Extends Licensing Agreement with INO Therapeutics 13
IBA Molecular Forms Joint Venture with Mallinckrodt 14
Terumo BCT Extends Distribution Agreement With Therakos 15
Terumo BCT Expands Agreement with Mallinckrodt 16
Mallinckrodt Pharma And Medtronic Enter Into Clinical Agreement For Intrathecal Therapeutics 17
Mallinckrodt Enters Into Co-Promotion Agreement With China Resources For Optiray 18
Ziehm Imaging Enters Into Agreement With Mallinckrodt For Vascular Applications 19
Debt Offering 20
Mallinckrodt to Raise up to USD1.2 Billion in Private Placement of Notes 20
Asset Transactions 21
IBA Molecular Acquires Nuclear Imaging Business from Mallinckrodt 21
Guerbet Acquires Contrast Media and Delivery Systems Business from Mallinckrodt for USD270 Million 23
MediBeacon Acquires Portfolio Of Optical Diagnostic Agent Development Assets From Mallinckrod 24
Acquisition 25
Mallinckrodt Acquires Stratatech 25
Mallinckrodt Pharma Acquires Therakos from Gores Group 26
Mallinckrodt Acquires Ikaria for up to USD2.3 Billion 28
MallInckrodt Plc – Key Competitors 30
MallInckrodt Plc – Key Employees 31
MallInckrodt Plc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 36
Strategy And Business Planning 36
Oct 16, 2017: Mallinckrodt Opens Specialty Brands Office In New Jersey, Announces $100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students 36
Sep 19, 2016: Mallinckrodt Grows Investment in Dublin College Business and Technology Park Site to €85 million 37
Aug 18, 2016: Mallinckrodt Locates Growing Specialty Brands Businesses In Bedminster, N.J.; Continues Significant St. Louis Reinvestment 38
Financial Announcements 39
Nov 07, 2017: Mallinckrodt Reports Earnings Results for Third Quarter of Fiscal 2017 39
Aug 08, 2017: Mallinckrodt Reports Earnings Results for Second Quarter of Fiscal 2017 41
May 08, 2017: Mallinckrodt Reports Earnings Results for First Quarter of Fiscal 2017 43
Feb 07, 2017: Mallinckrodt Reports Transition Period Results and Announces 2017 Guidance 45
Nov 29, 2016: Mallinckrodt Reports Fiscal 2016 Fourth Quarter and Full-Year Results 47
May 03, 2016: Mallinckrodt Reports Fiscal 2016 Second Quarter Results 49
Feb 02, 2016: Mallinckrodt Reports Fiscal 2016 First Quarter Results 51
Corporate Communications 53
Sep 19, 2016: Mallinckrodt Grows Investment in Dublin College Business and Technology Park Site to €85 million 53
May 23, 2016: Mallinckrodt Donates 250,000 Drug Deactivation Systems to ACT Missouri to Support Fight Against Prescription Drug Abuse 54
Other Significant Developments 55
Oct 04, 2017: Mallinckrodt Discusses Pipeline Transformation, Company Outlook at Investor Briefing 55
Jun 06, 2017: Mallinckrodt Updates Facts Refuting Short-Seller Claims 56
Apr 03, 2017: Mallinckrodt Statement on DEA and USAOs Agreement in Principle 58
May 18, 2016: Mallinckrodt to Change Fiscal Year 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
MallInckrodt Plc, Medical Equipment, Key Facts, 2016 2
MallInckrodt Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
MallInckrodt Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
MallInckrodt Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
MallInckrodt Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
MallInckrodt Plc, Deals By Market, 2011 to YTD 2017 9
MallInckrodt Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Gores Completes Acquisition Of Therakos From Ortho-Clinical Diagnostics 11
Mallinckrodt Enters into Licensing Agreement with NeuroproteXeon 12
Bellerophon Therapeutics Extends Licensing Agreement with INO Therapeutics 13
IBA Molecular Forms Joint Venture with Mallinckrodt 14
Terumo BCT Extends Distribution Agreement With Therakos 15
Terumo BCT Expands Agreement with Mallinckrodt 16
Mallinckrodt Pharma And Medtronic Enter Into Clinical Agreement For Intrathecal Therapeutics 17
Mallinckrodt Enters Into Co-Promotion Agreement With China Resources For Optiray 18
Ziehm Imaging Enters Into Agreement With Mallinckrodt For Vascular Applications 19
Mallinckrodt to Raise up to USD1.2 Billion in Private Placement of Notes 20
IBA Molecular Acquires Nuclear Imaging Business from Mallinckrodt 21
Guerbet Acquires Contrast Media and Delivery Systems Business from Mallinckrodt for USD270 Million 23
MediBeacon Acquires Portfolio Of Optical Diagnostic Agent Development Assets From Mallinckrod 24
Mallinckrodt Acquires Stratatech 25
Mallinckrodt Pharma Acquires Therakos from Gores Group 26
Mallinckrodt Acquires Ikaria for up to USD2.3 Billion 28
MallInckrodt Plc, Key Competitors 30
MallInckrodt Plc, Key Employees 31
MallInckrodt Plc, Other Locations 32
MallInckrodt Plc, Subsidiaries 32

★海外企業調査レポート[MallInckrodt Plc (MNK)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Commercial Bank Of Kuwait Sak:企業の戦略・SWOT・財務分析
    Commercial Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report Summary Commercial Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Yamaha Corporation (7951):企業の財務・戦略的SWOT分析
    Yamaha Corporation (7951) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Oakdale Electric Cooperative:企業の戦略的SWOT分析
    Oakdale Electric Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Can-Fite BioPharma Ltd (CANF):企業の財務・戦略的SWOT分析
    Summary Can-Fite BioPharma Ltd (Can-Fite) is a clinical stage drug development Company that strives to develop small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s pipeline products which are in phase II and III clinical development stage includes CF101, for rheu …
  • Invectys SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Invectys SA (Invectys) is a biopharmaceutical company that develops immunotherapy to treat cancer. The company provides product pipeline such as INVAC-1, a DNA vaccine targeting Telomerase; Universal Cancer Peptide vaccine UCPVax. It offers products such as a human telomerase peptide-based v …
  • Filtration Group Corporation:企業の戦略的SWOT分析
    Filtration Group Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Brookfield Property REIT Inc (GGP):企業の財務・戦略的SWOT分析
    Brookfield Property REIT Inc (GGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Apple Inc:企業の戦略・SWOT・財務情報
    Apple Inc - Strategy, SWOT and Corporate Finance Report Summary Apple Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Lexicon Pharmaceuticals Inc (LXRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program …
  • Ignyta Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ignyta Inc (Ignyta), formerly NexDx Inc, a subsidiary of F. Hoffmann-La Roche Ltd, is a cancer care service provider. The company discovers, develops and commercializes new drugs targeting activated genes in cancer cells. It develops products using integrated therapeutic technology (Rx/Dx). …
  • National Institute on Drug Abuse:製薬・医療:M&Aディール及び事業提携情報
    Summary National Institute on Drug Abuse (NIDA), a subsidiary of National Institutes of Health is a research institute that provides drug abuse and addiction services. The institute offers services in drugs of abuse such as bath salts, cocaine, heroin, inhalants, alcohol, club drugs, methamphetamine …
  • Almirall SA (ALM):企業の財務・戦略的SWOT分析
    Almirall SA (ALM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Berlin Packaging, LLC.:企業の戦略・SWOT・財務情報
    Berlin Packaging, LLC. - Strategy, SWOT and Corporate Finance Report Summary Berlin Packaging, LLC. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Bio Pappel, S.A.B. de C.V.:企業の戦略・SWOT・財務情報
    Bio Pappel, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Bio Pappel, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Cogstate Ltd (CGS)-製薬・医療分野:企業M&A・提携分析
    Summary Cogstate Ltd (Cogstate) is a cognitive science company that provides technology solutions. The company offers scientific consulting, precision recruitment and computerized assessment, among others. It also provides drug development strategies, protocol design, test selection for screening, s …
  • TesoRx Pharma LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary TesoRx Pharma LLC (TesoRx) is a pharmaceutical company that develops treatments to address unmet medical needs. The company’s product pipeline comprises TSD-001, TSD-005, TSX-011 and TSX-002. Its TSD-001is an intravesical paclitaxel for the treatment of non-muscle invasive bladder cancer. Te …
  • The McClatchy Company:企業の戦略・SWOT・財務情報
    The McClatchy Company - Strategy, SWOT and Corporate Finance Report Summary The McClatchy Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sequenom Inc-医療機器分野:企業M&A・提携分析
    Summary Sequenom Inc (Sequenom) is a life sciences company which offers genetic testing that guides reproductive health matters. The company operates CAP (College of American Pathologists) accredited and CLIA (Clinical Laboratory Improvements Amendment) certified molecular diagnostics clinical labor …
  • China Medical System Holdings Ltd (867):企業の財務・戦略的SWOT分析
    Summary China Medical System Holdings Ltd (CMS) is a pharmaceutical service provider that markets, promotes, and sells prescription drugs to all therapeutic departments in hospitals. The company offers products such as deanxit, ursofalk, augentropfen stulln mono eye-drops, exacin, xinhuosu, salofalk …
  • CooperSurgical Inc:医療機器:M&Aディール及び事業提携情報
    Summary CooperSurgical Inc (CooperSurgical), a subsidiary of The Cooper Companies Inc is a medical device company that offers surgical instrument. The company offers surgical products, clinic and office products, labor and delivery products, and critical care products. Its surgical products include …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆